dc.contributor.author | Cahill, Leah E. | |
dc.contributor.author | Levy, Andrew P. | |
dc.contributor.author | Chiuve, Stephanie E. | |
dc.contributor.author | Jensen, Majken K. | |
dc.contributor.author | Wang, Hong | |
dc.contributor.author | Shara, Nawar M. | |
dc.contributor.author | Blum, Shany | |
dc.contributor.author | Howard, Barbara V. | |
dc.contributor.author | Pai, Jennifer K. | |
dc.contributor.author | Mukamal, Kenneth J. | |
dc.contributor.author | Rexrode, Kathryn M. | |
dc.contributor.author | Rimm, Eric Bruce::0ab2926c8242f35e5a982e3cf59f4987::600 | |
dc.date.accessioned | 2019-08-26T13:59:41Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Cahill, Leah E., Andrew P. Levy, Stephanie E. Chiuve, Majken K. Jensen, Hong Wang, Nawar M. Shara, Shany Blum, et al. 2013. “Haptoglobin Genotype Is a Consistent Marker of Coronary Heart Disease Risk Among Individuals With Elevated Glycosylated Hemoglobin.” Journal of the American College of Cardiology 61 (7): 728–37. https://doi.org/10.1016/j.jacc.2012.09.063. | |
dc.identifier.issn | 0735-1097 | |
dc.identifier.issn | 1558-3597 | |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:41246942 | * |
dc.description.abstract | Objectives This study sought to investigate into the biologically plausible interaction between the common haptoglobin (Hp) polymorphism rs#72294371 and glycosylated hemoglobin (HbA(1c)) on risk of coronary heart disease (CHD).Background Studies of the association between the Hp polymorphism and CHD report inconsistent results. Individuals with the Hp2-2 genotype produce Hp proteins with an impaired ability to prevent oxidative injury caused by elevated HbA(1c).Methods HbA(1c) concentration and Hp genotype were determined for 407 CHD cases matched 1:1 to controls (from the NHS [Nurses' Health Study]) and in a replication cohort of 2,070 individuals who served as the nontreatment group in the ICARE (Prevention of Cardiovascular Complications in Diabetic Patients With Vitamin E Treatment) study, with 29 CHD events during follow-up. Multivariate models were adjusted for lifestyle and CHD risk factors as appropriate. A pooled analysis was conducted of NHS, ICARE, and the 1 previously published analysis (a cardiovascular disease case-control sample from the Strong Heart Study).Results In the NHS, Hp2-2 genotype (39% frequency) was strongly related to CHD risk only among individuals with elevated HbA(1c) (>= 6.5%), an association that was similar in the ICARE trial and the Strong Heart Study. In a pooled analysis, participants with both the Hp2-2 genotype and elevated HbA(1c) had a relative risk of 7.90 (95% confidence Interval: 4.43 to 14.10) for CHD compared with participants with both an Hp1 allele and HbA(1c) <6.5% (p for interaction = 0.004), whereas the Hp2-2 genotype with HbA(1c) <6.5% was not associated with risk (relative risk: 1.34 [95% confidence interval: 0.73 to 2.46]).Conclusions Hp genotype was a significant predictor of CHD among individuals with elevated HbA(1c). (J Am Coll Cardiol 2013; 61: 728-37) c 2013 by the American College of Cardiology Foundation | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | |
dash.license | OAP | |
dc.title | Haptoglobin Genotype Is a Consistent Marker of Coronary Heart Disease Risk Among Individuals with Elevated Glycosylated Hemoglobin | |
dc.type | Journal Article | |
dc.description.version | Accepted Manuscript | |
dc.relation.journal | Journal of the American College of Cardiology (JACC) | |
dash.depositing.author | Rimm, Eric Bruce::0ab2926c8242f35e5a982e3cf59f4987::600 | |
dc.date.available | 2019-08-26T13:59:41Z | |
dash.workflow.comments | 1Science Serial ID 55952 | |
dc.identifier.doi | 10.1016/j.jacc.2012.09.063 | |
dash.source.volume | 61;7 | |
dash.source.page | 728 | |